OPCH · CIK 1014739
What Option Care Health, Inc. told the SEC could break it.
Option Care's sharpest exposure is drug-pricing policy: the Inflation Reduction Act lets CMS negotiate Medicare Part D prices, and the first round cut one therapy in its portfolio by 66% from its 2023 list price effective January 2026, with ongoing negotiations expected to keep pressuring results. Its revenue is also essentially all reimbursement-dependent — 88% from managed-care and other non-government payers and 12% from Medicare/Medicaid — with its single largest payer about 14% of 2025 revenue, so rate pressure or loss there would hurt. And it carries $1,176.3 million of outstanding borrowings (a first-lien term loan plus $500 million of 4.375% notes due 2029), which could divert cash to debt service and constrain liquidity and growth.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- IRA Medicare Part D drug price negotiationhigh
The Inflation Reduction Act lets CMS negotiate Medicare Part D drug prices; the first round cut one therapy in Option Care's portfolio by 66% from 2023 list price effective January 2026, and ongoing IRA-mandated negotiations and CMS determinations are expected to keep pressuring results.
“In August 2024, CMS announced the results of its first round of drug price negotiations, which included a 66% reduction from 2023 list price for one therapy in our portfolio effective January 2026.”
Customer concentration
- Third-party payer concentration (largest payer 14%)medium
Essentially all revenue is reimbursement-dependent — 88% from MCOs and other non-government payers and 12% from Medicare/Medicaid — and the single largest payer accounted for about 14% of revenue in 2025 (15% in 2024), so loss of or rate pressure from that payer would materially hit results.
“Revenue related to the Company's largest payer was approximately 14 %, 15 %, and 14 % for the years ended December 31, 2025, 2024, and 2023, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the years presented.”
SEC filing →As of 2026
Liquidity & debt
- Outstanding borrowings ($1.18B)medium
Carries $1,176.3 million of outstanding borrowings (a First Lien Term Loan plus $500M of 4.375% Senior Unsecured Notes due 2029) that could divert cash to debt service and constrain liquidity and growth investment.
“As of December 31, 2025, we had $1,176.3 million of outstanding borrowings”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch